Navigation Links
CuraGen Announces Top-Line Phase II Results on Velafermin
Date:10/11/2007

Tuesday, October 23, 2007

Poster Board: A68

Session: Poster Session A: Biological Therapeutic Agents

Upcoming Presentations at the 2007 ASH Annual Meeting, December 8-11, 2007 in Atlanta, GA:

Belinostat

Title: Belinostat (PXD101) in Patients with Recurrent or

Refractory Peripheral or Cutaneous T-Cell Lymphoma:

Results of a Phase II Study

Date: Monday, December 10, 2007

Poster Board: 2607

Session: Lymphoma: Chemotherapy, excluding Pre-Clinical Models:

Diffuse Large Cell Lymphoma and T-Cell Lymphoma

Velafermin

Title: A Randomized Placebo Controlled Phase II Trial of

Prevention of Severe Oral Mucositis Using Single Dose

Velafermin in Patients Receiving Myeloablative Therapy and

Autologous Hematopoietic Stem Cell Transplant (AHSCT)

Date: December 10, 2007

Time: 4:00 p.m. Eastern Time

Session: Clinical Care: Transplantation Regimen Toxicities and

Engraftment-Regimen-Related Toxicities

About CuraGen

CuraGen Corporation (Nasdaq: CRGN) is a dedicated clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer including belinostat and CR011-vcMMAE. By leveraging the drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of cancer patients. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit

SOURCE CuraGen Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. CuraGen Presents Update on Clinical Development Program for Belinostat
2. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
3. CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...OREST, Ill., Dec. 4 Hosp...ty pharmaceutical and medication delivery company,... 50 mL and 100 mL VisIV(TM) containers for intrave...ers a complete size range (50 mL to 1 L) of the aw...duct. The launch of the 50 mL and 100 mL container...
(Date:12/4/2009)... Dec. 4 Axsun Technologi...poration (Nasdaq: VOLC ), today announced the ini... integrated light source architecture for OCT imag...ne design raises the bar on imaging speed and over...ns for swept source OCT light sources. This appro...
(Date:12/4/2009)... Drs. Neal Shore and E. David Craw...en (PSA) recurrence from the additional analysis o...ate in a Phase III pivotal study of FIRMAGON®...rolide in prostate cancer patients during the firs... received FIRMAGON 240/80 mg/month had a recurrenc...
Breaking Medicine Technology:Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Video 3A Axel Ullrich Named Winner of 2009 Dr Paul Janssen Award for Biomedical Research 12873 1Video 3A Axel Ullrich Named Winner of 2009 Dr Paul Janssen Award for Biomedical Research 12873 2Video 3A Axel Ullrich Named Winner of 2009 Dr Paul Janssen Award for Biomedical Research 12873 3Video 3A Axel Ullrich Named Winner of 2009 Dr Paul Janssen Award for Biomedical Research 12873 4Video 3A Axel Ullrich Named Winner of 2009 Dr Paul Janssen Award for Biomedical Research 12873 5New York Citys World Product Centre Announces Initial Charter Partners 50551 1New York Citys World Product Centre Announces Initial Charter Partners 50551 2New York Citys World Product Centre Announces Initial Charter Partners 50551 3New York Citys World Product Centre Announces Initial Charter Partners 50551 4Celiac Disease Making Inroads in U S 50549 1Celiac Disease Making Inroads in U S 50549 2
...doption of Safe, Non-Drug Option to Lower Blood Pr...NEW YORK, Jan. 24 InterCure, Ltd. (Tel Aviv Stock...hypertension treatment,device, clinically-proven t...ced it sold its 100,000th RESPeRATE device during ...riod of widespread consumer adoption and,physician...
...cribing behavior appear inconsistent with ACC stat...sults, MOUNT LAUREL, N.J., Jan. 24 ImpactRx, Inc... pharmaceutical promotion on,physicians, prescribi...p in,prescribing Zetia and Vytorin since Merck / S...lts on January 14. That study was designed to,dete...
Other Medicine Technology:InterCure Announces 100,000th RESPeRATE Unit Sold 2InterCure Announces 100,000th RESPeRATE Unit Sold 3ImpactRx Tracks Decline in Zetia and Vytorin Prescribing 2ImpactRx Tracks Decline in Zetia and Vytorin Prescribing 3
(Date:12/4/2009)...itate to take breast cancer drug, study finds , ...es about side effects are a major reason why only ...t cancer are willing to take the drug tamoxifen to...n effort to inform women about the risks and benef... Michigan Comprehensive Cancer Center created a de...
(Date:12/4/2009)...ntor Showcasing Innovative Health Product in Scott...4, 2009 -- A valley inventor garnering national at...ls lose weight, prevent disease, restore health, i...ing the product at Saturday’s Technology Fai...rekDesk has been featured on major television net...
(Date:12/4/2009)...Dec. 4 Today, seven of Florida,s t...proving the health of Florida,s uninsured and unde...da,s 2009 Sapphire Award ceremony. ,, The Sapph...ecognizes and promotes organizations that have dem...ies within their communities. ,, Honorees of Th...
(Date:12/4/2009)...wire-USNewswire/ -- As Congress prepares to vote o...ncil (FRC) today announced an eight week campaign ...y each household on provisions of the Senate healt...oning, higher taxes, and government-run health car...express opposition to the so-called health care re...
(Date:12/4/2009)...ewswire-FirstCall/ -- Movado Group Inc. (NYSE: M...tlanta, Georgia, shared in a tribute on December 3...Melanie Oudin for her stellar performance in the t...arterfinalist at the Open since 1999. ,, (Phot...NY21184 ) ,, At a celebratory reception held at...
Breaking Medicine News(10 mins):Health News:High-Risk Women May Often Avoid Using Tamoxifen 2Health News:Valley Health Invention Making National Splash Showcased at Scottsdale Civic Center Gallery 2Health News:Top Nonprofits Honored for Improving Health of Floridians 2Health News:Top Nonprofits Honored for Improving Health of Floridians 3Health News:FRC Announces Campaign to Call Every Louisiana Household, Urging Opposition to Health Care Takeover 2
...pies found medications cut withdrawal, urge to dri... Sticking to a regimen of prescribed medications i...toms and urges to drink alcohol in those being tre...o behavioral treatments -- low-intensity medical m...
...ric, an Asian spice found in many curries, has a l...ng wounds and relieving pain, but can it prevent d...ny diseases and is believed to be involved in onse...ia University Medical Center, and his colleagues w...
...ves head in fundraising challenge, MILLERSVILLE, ...tionwide leader in wholesale vacation accommodatio... for juvenile alopecia,areata, an autoimmune disor...,promised to shave his head if TAN employees reach...
... candlelight ceremony in Newark, NEWARK, N.J., Ju...ogether Saturday night to celebrate cancer survivo...he disease at an overnight event,in Newark., Team...The event is held overnight to represent the fact ...
... having both a sexually transmitted disease (STD) ...uring early pregnancy were four times more likely ...fect in which infants are born with their intestin...he researchers caution must be verified with furth...
...a threefold increased risk of disease, report says...heumatoid arthritis (RA) patients treated with met...and other cancers, an Australian study says. , Me...ggested, and there are even concerns that the drug...
Other Medicine News:Health News:Prescribed Meds Still Best Treatment for Alcoholism 2Health News:Common cooking spice shows promise in combating diabetes and obesity 2Health News:TAN Employees Shave the Way for the Fight Against Alopecia 2Health News:Sexually transmitted disease, urinary tract infections may be bad combination for birth defect 2Health News:Sexually transmitted disease, urinary tract infections may be bad combination for birth defect 3Health News:Rheumatoid Arthritis Drug Boosts Melanoma Incidence 2
Goat Anti-Human IgA, alpha chain Antibody, Colloidal Gold Conjugated, 50 OD
Protein A 50 OD, Colloidal Gold Conjugated/Tagged
Protein A, Gold Ribbon - .25 OD per sq. cm.
Protein G, Gold Ribbon - .50 OD per sq. cm.
Medicine Products: